Critical Contrast: Harrow (NASDAQ:HROW) versus Liquidia (NASDAQ:LQDA)

Harrow (NASDAQ:HROW) and Liquidia (NASDAQ:LQDA) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, risk, profitability, earnings, analyst recommendations, institutional ownership and valuation.

Analyst Ratings

This is a summary of current ratings and price targets for Harrow and Liquidia, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Harrow	2	1	7	0	2.50
Liquidia	2	4	5	1	2.42

Harrow presently has a consensus target price of $66.17, suggesting a potential upside of 145.56%. Liquidia has a consensus target price of $72.85, suggesting a potential upside of 52.21%. Given Harrow’s stronger consensus rating and higher possible upside, equities research analysts clearly believe Harrow is more favorable than Liquidia.

Risk and Volatility

Harrow has a beta of 0.18, suggesting that its share price is 82% less volatile than the S&P 500. Comparatively, Liquidia has a beta of 0.4, suggesting that its share price is 60% less volatile than the S&P 500.

Profitability

This table compares Harrow and Liquidia’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Harrow	-13.51%	-38.00%	-3.37%
Liquidia	30.74%	149.65%	36.30%

Earnings & Valuation

This table compares Harrow and Liquidia”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Harrow	$272.30 million	3.71	-$5.14 million	($1.00)	-26.95
Liquidia	$158.32 million	27.06	-$68.92 million	$1.37	34.93

Harrow has higher revenue and earnings than Liquidia. Harrow is trading at a lower price-to-earnings ratio than Liquidia, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

72.8% of Harrow shares are held by institutional investors. Comparatively, 64.5% of Liquidia shares are held by institutional investors. 12.8% of Harrow shares are held by company insiders. Comparatively, 25.6% of Liquidia shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Liquidia beats Harrow on 9 of the 15 factors compared between the two stocks.

About Harrow

Harrow, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in Nashville, Tennessee.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion. The company also a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.